
Avidity submits Biological License Application (BLA) to the FDA, seeking approval for exon 44-skipping “del zota”
Exon 44 Skipping CureDuchenne was an early funder of Avidity Biosciences, which is now a Novartis company. We are pleased to share that they have submitted a BLA to the […]








